Active	Status	Sponsor type	Region	Phase	Filter
1 Active 18 Inactive 19 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Orfadin (nitisinone) / Astellas, SOBI
Sobi.NTBC-008, NCT06227429: A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients	Recruiting	N/A	15	RoW	Nitisinone, Orfadin®	Swedish Orphan Biovitrum	Hereditary Tyrosinemia, Type I	06/27	06/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Orfadin (nitisinone) / Astellas, SOBI
Sobi.NTBC-008, NCT06227429: A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients	Recruiting	N/A	15	RoW	Nitisinone, Orfadin®	Swedish Orphan Biovitrum	Hereditary Tyrosinemia, Type I	06/27	06/27